Characterization of Genetic Variants in the SLC5A5 Gene and Associations With Breast Milk Iodine Concentration in Lactating Women of African Descent: The NUPED Study

Sicelosethu S. Siro 1, Jeannine Baumgartner 1,2, Maryke Schoonen 1, Jennifer Ngounda 3, Linda Malan 1, Elizabeth A. Symington 4, Cornelius M. Smuts 1 and Lizelle Zandberg 1*

1 Centre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa, 2 Human Nutrition Laboratory, Department of Health Sciences and Technology, Institute of Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland, 3 Department of Nutrition and Dietetics, University of the Free State, Bloemfontein, South Africa, 4 Department of Life and Consumer Sciences, University of South Africa, Johannesburg, South Africa

Background: The sodium iodide symporter is responsible for the transfer of iodine into breast milk and is encoded for by the SLC5A5 gene. The role of genetic variants in the SLC5A5 gene locus in relation to the transfer of iodine from plasma into breast milk in healthy lactating individuals has, to our knowledge, not been explored.

Objective: To identify and characterize possible genetic variants of the SLC5A5 gene in women of African descent living in urban South Africa, and to study associations with breast milk iodine concentrations (BMIC) in lactating women.

Methods: This study is affiliated to the Nutrition during Pregnancy and Early Development (NuPED) cohort study (n = 250 enrolled pregnant women). In a randomly selected sub-sample of 32 women, the SLC5A5 gene was sequenced to identify known and novel variants. Of the identified variants, genotyping of selected variants was performed in all pregnant women who gave consent for genetic analyses (n = 246), to determine the frequency of the variants in the study sample. Urinary iodine concentration (UIC) in spot urine samples and BMIC were measured to determine iodine status. Associations of SLC5A5 genetic variants with BMIC were studied in lactating women (n = 55).

Results: We identified 27 variants from sequencing of gene exomes and 10 variants were selected for further study. There was a significant difference in BMIC between the genotypes of the rs775249401 variant (P = 0.042), with the homozygous GG group having lower BMIC [86.8 (54.9–167.9) µg/L] compared to the (A) allele carriers rs775249401(AG+AA) [143.9 (122.4–169.3) µg/L] (P = 0.042). Of the rs775249401(GG), 49% had UIC < 100 µg/L and 61% had BMIC < 100 µg/L. On the other hand, 60% of the rs775249401(AG+AA) carriers had UIC < 100 µg/L, and none had a BMIC < 100 µg/L.
INTRODUCTION

The sodium iodide symporter (NIS) is an intrinsic plasma membrane glycoprotein mediating iodide uptake into thyroid follicular cells. The NIS protein consisting of 643 amino acids is encoded by the SLC5A5 gene, which is located on the forward strand of chromosome 19 (19: 17,982,754–18,005,983, GRCh37.p12) with an open reading frame consisting of 1929 nucleotides arranged as 14 introns and 15 exons (1). The NIS plays a crucial role in iodine metabolism and thyroid regulation (2). Besides thyroid hormone synthesis, the NIS is expressed in breast tissue during late pregnancy and lactation and is responsible for the transfer of iodine from plasma into mammary epithelial cells of lactating breasts (3).

Breast milk is a crucial source of iodine for the breastfeeding infant (4). Thus, adequate breast milk iodine concentration (BMIC) is important for meeting the iodine requirements of infants. Maternal iodine intake, estimated by measuring urinary iodine concentration (UIC), is known to greatly influence BMIC. Therefore, lactating women with insufficient iodine intake reportedly excrete insufficient breast milk iodine to meet the infants’ needs (4–6). BMIC of 92 to 150 µg/L have been suggested to provide sufficient iodine to infants (6–8), but consensus on a BMIC threshold to define adequate iodine nutrition has not yet been reached. However, mean and median BMIC values were shown to vary widely between areas, with values typically ranging from <50 µg/L in iodine-deficient areas (4) to 100–150 µg/L in areas of iodine sufficiency (7) but being as high as 150–180 µg/L in areas of adequate iodine supply (9, 10). In a previous cross-sectional study in a convenience sample of 100 lactating women living in a semi-urban area of South Africa, we observed a median BMIC of 179 (126–269) µg/L with large inter-individual variations (11).

Previous research has shown that there is a preferential fractional excretion of iodine in breast milk rather than urine among participants with poor iodine status living in iodine sufficient regions (12). Additionally, women from iodine-deficient regions showed a constant partitioning of iodine into breastmilk. As such, participants with suboptimal iodine status have been shown to present with adequate BMIC. This could be explained by a protective mechanism that allows for a steady supply of iodide to breastfed infants of lactating women with suboptimal iodine status (12, 13), and the NIS is likely to play a major role.

Since there are limited data available on the role of genetic variants in the SLC5A5 gene in relation to breast milk iodine concentration, we aimed to characterize genetic variants in the SLC5A5 gene of women of African descent living in urban South Africa. Further, we investigated the relationship between selected variants with breast milk iodine concentration in lactating women.

MATERIALS AND METHODS

Study Design and Site

The NuPED study was a prospective cohort study conducted in Johannesburg, South Africa from March 2016 to July 2018. The study protocol has been previously published (14). In brief, pregnant women (n = 250) were enrolled if they were between 18 and 39 years of age, <18 weeks gestational age, born in South Africa or a neighboring country, have lived in Johannesburg for at least 12 months, were able to communicate effectively in one of the local languages, non-smoking, and expecting a singleton. Pregnant women were excluded from participation if they reported use of illicit drugs, had a known non-communicable disease such as diabetes, renal disease, history of high blood cholesterol and hypertension, and had a known infectious disease such as tuberculosis or hepatitis, or known serious illness such as cancer, lupus or psychosis. HIV positive women were included in the study. Pregnant women were assessed at <18, 22, and 36 weeks gestation. Follow-up assessments in the women and their infants were performed at 6, 7.5, and 12 months after birth. Of the 250 enrolled women, a total of 98 mother-infant pairs participated in the 6-month follow-up.

In a randomly selected sub-sample of 32 women, the SLC5A5 gene was sequenced to identify and characterize genetic variants. Of the identified variants, genotyping of selected variants was performed in all pregnant women enrolled in the NuPED study and who gave consent for genetic analyses (n = 246), to determine the frequency of the variants in the study sample.

This study was conducted according to the guidelines of the Declaration of Helsinki and all procedures involving human participants were approved by the Human Research Ethics Committees (HREC) of the North-West University (NWU-00186-15-A1 for the NuPED pregnancy phase, NWU-00049-16-A1 for the postnatal phase) and the University of the Witwatersrand, Johannesburg (M150968 and M161045). These studies were also reviewed by the Rahima Moosa Mother and Child Hospital (RMMCH) research review committee, the Gauteng Department of Health, and the Johannesburg Health

Conclusion: Our results suggest that A-allele carriers of rs775249401 (AG+AA) are likely to have higher iodine transfer into breast milk compared to the homozygous GG counterparts. Thus, genetic variations in the SLC5A5 gene may play an important role in the transfer of iodine from plasma into breast milk and may partially explain inter-individual variability in BMIC.

Keywords: breast milk, iodine concentration, lactating women, SLC5A5 gene, sodium iodide symporter, urinary iodine concentration
District’s District Research Committee. Further ethical approval was granted for this sub-study by the North-West University HREC (NWU-00455-19-S1 for this study). All participants gave written informed consent.

**Blood Sample Collection and Genetic Analysis**

**Genomic DNA Isolation and Next-Generation Sequencing**

A venous blood sample was collected into trace element-free ethylenediaminetetraacetic acid (EDTA)-coated vacutainer tubes via venepuncture of the antecubital area of the arm. Blood samples were processed by centrifugation (at 2,000 rpm for 15 min) within 1 h after blood collection to separate plasma, red blood cells and Buffy coat. The buffy coat was aliquoted and stored in a 1:1 vol:vol RNAlater (Ambion, Thermo Fischer Scientific) on-site at −20°C for a maximum of seven days. The samples were then transported on dry ice to the Centre of Excellence for Nutrition (CEN) laboratories in Potchefstroom, South Africa and stored at −80°C for genomic DNA (gDNA) isolation.

Genomic DNA (gDNA) was isolated from buffy coat using the Maxwell® 16 instrument and Maxwell® 16 DNA Purification Kit (AS1010) (Promega Corporation) following the manufacturer’s instructions. Quantification of gDNA was done using the NanoDrop® ND-1000 UV-Vis Spectrophotometer (Thermo Fischer Scientific).

Massively parallel next-generation sequencing (NGS) was performed using the Ion Torrent platform on the subset of 32 randomly selected samples. A custom Ion Ampliseq panel was designed with the online Ampliseq designer (https://ampliseq.com/), last accessed July 2020. This customized panel included the SLC5A5 gene locus spanning a target region size of 20.83 kbp with 20 amplicons covering 100% of the targeted sequence. Library preparation was performed on the Ion Chef® as per the manufacturers specifications. A total of 10 ng gDNA (0.67 ng/µl) was used as input volume for library preparation. Library and template preparation were done with the Ion AmpliSeq™ Kit for Chef DL8 for 32 reactions (Cat number: A29024), and the Ion 510™ and Ion 520™ and Ion 530™ Kit—Chef (Cat number A34019), respectively. The entire coding region of each selected gene, including flanking regions of introns-exons was sequenced according to 200bp chemistry, using an Ion 530™ Chip Kit-4 Reactions (Cat number: A27763) and the Ion S5™ System (Cat number: A27212, ThermoFisher, MA, USA).

Data analysis of raw reads obtained from the Ion S5™ System was done with the Torrent Suite (v.5.8). The fastq files were uploaded to the sequence reads archive Bioproject PRJNA735618. The primary analysis included signal calling and base-calling. Quality control of the bases was filtered according to a Phred quality score of 20, depth > 10 and quality score of >500 freds were met. The sequence files were aligned against Genome Reference Consortium Human Build 37 (hg19), followed by coverage analysis and variant calling using the coverage analysis and variantCaller plugins from the Torrent Suite, respectively. Secondary data analyses of the variant caller files were annotated, filtered and mined following an in-house pipeline (15).

**Variant Selection, Genotyping, and Quality Assessment**

In the subset of 32 sequenced samples, variants that passed the quality control assessment were considered for validation in the entire sample set using the iPLEX® MassARRAY system from Agena Bioscience™. iPLEX assays were designed and analyses were performed by the service provider Inqaba Biotech (Inqaba Biotechnology Pretoria South Africa). Assays were designed using the Assay Design Suite (ADS) software and dbSNP for metadata. gDNA was amplified in 96 microtiter plates using iPLEX reagent kits and a nano dispenser RS1000 was used to transfer samples from microtiter plates to a SpectroCHIP® array. Data were obtained from the SpectroCHIP® array using the MassARRAY® analyser. Reports were automatically generated by Typer (Company). Genotype calls were made in real-time during MALDI-TOF analysis and data was automatically saved to the MassARRAY database. Variants were assessed for quality, and tested for adherence to Hardy-Weinberg equilibrium (HWE) (16) by using Haploviz and modified Pearson chi-square (χ²) test. Adherence to HWE was set at P < 0.001.

**Urine Sample Collection and Iodine Analysis**

From the 98 women participating in the 6-month follow-up, we collected a midstream spot urine sample (10–40 ml) into clean polystyrene cups between 07:00 and 12:00 noon, and approximately 5 ml was decanted into iodine-free screw-capped cups. The research team ensured that the urine samples were not used for any routine assessments using dipsticks (potential contamination with iodine). Samples were aliquoted and stored on-site at −20°C for a maximum of 7 days. Thereafter, samples were transported on dry ice to the CEN laboratories, for storage at −80°C until analysis.

Urineary iodine concentration (UIC) in spot urine samples was measured in duplicate using the Pino modification of the Sandell-Kolthoff reaction with spectrophotometric detection at CEN laboratories (17, 18). All analyses were done using nanopure grade water and all laboratory glassware and plasticware were acid washed before use. Internal and external controls were used to ensure the quality of the analysis. Iodine concentrations in spot urine samples are expressed as median concentrations (µg/L). A UIC cut-off of <100 µg/L was used to indicate insufficient iodine intake in lactating women (19).

**Breast Milk Sample Collection and Iodine Analysis**

From 58 lactating women who participated in the 6-month follow-up, a breast milk (foremilk) sample (~5 ml) was collected by manual expression into an iodine-free screw-capped cup before feeding the infant. Iodine concentrations in breast milk (in µg/L) were measured using a multi-collector inductively coupled plasma mass spectrometer [MC-ICP-MS (Finnigan NEPTUNE, Thermo Scientific™ Waltham, MA, USA)] as described by Dold.
et al. (10). A BMIC cut-off of <100 µg/L was used to indicate inadequate maternal iodine intake (20).

**Iodine Excretion Calculations**

Individual UIC and BMIC measures were used to calculate the estimated daily iodine excretion through the urine and breast milk by assuming a total daily urine volume of 1.5 L (12, 21, 22) and breast milk volume of 0.78 L (12, 22). Estimated total daily iodine excretion was calculated as the iodine excretion in urine added to the iodine excretion in breast milk (12). Furthermore, fractional iodine excretion in urine and breast milk as percentages of estimated total daily iodine excretion were also calculated (12, 22).

**Statistical Analyses**

Raw data were captured in Microsoft Access and 20% of all data were randomly checked for correctness. All genetic, UIC and BMIC, data were captured in Excel Windows XP (Microsoft, Seattle, WA, USA). Data processing and statistical analysis of data were performed using SPSS software (SPSS Inc, Chicago, IL, USA).

Data were tested for normality using the Kolmogorov-Smirnov test. UIC and BMIC data were log-transformed for further analysis. For UIC, values above the cut-off indicative of excessive iodine intake (UIC >500 µg/L) were considered outliers. These UIC outliers (n = 2) were excluded from the analysis because high intakes of iodine have previously been reported to lead to improved BMIC in an individual that harbored a SLC5A5 variant associated with the lower transfer of iodine into breast milk (23). Normally and non-normally distributed data are expressed as means ± standard deviation (SD) and medians (25th percentile, 75th percentile), respectively. Categorical data are expressed as frequencies and percentages.

---

**TABLE 1 | Genetic variants identified with next generation sequencing.**

| Reference ID | Location bp | Reference allele | Alternative allele | Exon | Variant type | Minor allele frequency (MAF) |
|--------------|-------------|-----------------|-------------------|------|--------------|-----------------------------|
| **Annotated variants** | | | | | | |
| 1 rs371875541 | 17983314 | G | T | 1/15<sup>a</sup> | synonymous | 0.031 |
| 2 rs775249401 | 17985454 | G | A | intron | 0.125 |
| 3 rs55910163 | 17994635 | C | T | intron | 0.188 |
| 4 rs866765676 | 17982992 | C | T | 1/15 | 5′ UTR | 0.031 |
| 5 rs73518702 | 17983105 | C | A | 1/15 | 5′ UTR | 0.188 |
| 6 rs575147988 | 17983038 | C | T | 1/15 | 5′ UTR | 0.063 |
| 7 rs34850963 | 17983503 | G | T | intron | 0.125 |
| 8 rs150814476 | 17988717 | C | G | intron | 0.125 |
| 9 rs116154266 | 17983093 | C | T | 1/15 | 5′ prime UTR | 0.063 |
| 10 rs8103545 | 17986763 | C | T | 5/15 | Splice site | 0.188 |
| 11 rs35209636 | 17988794 | C | T | 7/15 | synonymous | 0.188 |
| 12 rs73520743 | 17994573 | A | C | 11/15 | synonymous | 0.313 |
| 13 rs112076606 | 17994594 | A | G | intron | 0.281 |
| 14 rs73520745 | 17994836 | G | A | 12/15 | missense | 0.188 |
| 15 rs4808708 | 18001886 | G | A | intron | 0.281 |
| 16 rs4808709 | 18001839 | A | G | intron | 0.438 |
| 17 rs11207649 | 17983075 | C | T | 1/15 | 5′ UTR | 0.094 |
| 18 rs77947605 | 17994644 | C | T | intron | 0.188 |
| 19 rs118133504 | 17983059 | C | T | 1/15 | 5′ UTR | 0.031 |
| 20 rs113740666 | 17985371 | AT | A | intron | 0.031 |
| 21 rs369522814 | 17994641 | C | G | intron | 0.063 |
| 22 rs121909177 | 17999206 | C | T | 13/15 | synonymous | 0.031 |
| 23 rs7255301 | 17984834 | G | A | intron | 0.313 |
| 24 rs200966271 | 17994619 | A | C | intron | 0.031 |
| 25 rs8108188 | 17988825 | T | G | 7/15 | missense | 0.031 |
| 26 rs190567881 | 17988721 | C | G | intron | 0.031 |
| **Novel variants** | | | | | | |
| 1 | 17983034 | C | T<sup>c</sup> | 1/15 | 5′ UTR | 0.188 |
| 2 | 17999293 | G | C<sup>c</sup> | intron | 0.031 |
| 3 | 17999295 | T | A<sup>c</sup> | intron | 0.031 |

<sup>a</sup>Source: Ensembl release 96—April 2019, retrieved 03 April 2019 (24).<sup>b</sup>Exon number in which the single nucleotide is found out of the 15 exons of the SLC5A5 gene.<sup>c</sup>Alternative allele as observed in our population.
Participants were stratified according to UIC categories (UIC < 100 µg/L and UIC ≥ 100 µg/L) or BMIC categories (BMIC < 100 µg/L and BMIC ≥ 100 µg/L). The between-group analyses were performed using the Mann Whitney U test. Overlaid scatterplots were used to depict the relationship between total daily iodine excretion, fractional iodine excretion in breast milk and fractional iodine excretion in urine. Unadjusted linear models were performed to compare UIC and BMIC between genetic variants with the recessive genetic model (GG vs. GA + AA) as categorical variables. For the significant models, effect sizes were calculated using Cohen’s $d$ and partial eta squared. Significance was set at $p < 0.05$.

RESULTS

Characterization of the Genetic Variants in the SLC5A5 Gene Locus

Genomic DNA was isolated from 246 samples and the SLC5A5 gene of 32 randomly selected samples were sequenced following a targeted gene sequencing approach. Variants were quality controlled and 27 genetic variations passed the quality control assessment. Of the 27 variants, 26 had known annotation and one was novel located in the 5’ untranslated region (UTR). Of the annotated variants, six were coding and 13 were in intronic regions, whereas the remaining seven variants were located in the 5’ UTR (Table 1). Variants were inspected for functionality based on genomic position as well as intronic regions, whereas the remaining seven variants were located in the 5’ UTR (Table 1). Variants were inspected for the recessive genetic model (GG vs. GA + AA) as categorical variables. For the significant models, effect sizes were calculated using Cohen’s $d$ and partial eta squared. Significance was set at $p < 0.05$.

| Allele | HWE | MAF | Genotype (n) | HWE | MAF | Genotype (n) |
|--------|-----|-----|--------------|-----|-----|--------------|
| Chr:bp | | | | Chr:bp | | |
| rs121909177 | 19:17888397 | Exon | C:T | 1.0 | 0.007 | 225 | 3 | - | 1.0 | 0 | 52 | - |
| rs4880708 | 19:17890877 | Intron | G:A | 1.0 | 0.137 | 176 | 56 | 4 | 1.0 | 0.087 | 41 | 11 | 1 |
| rs7255301 | 19:17874025 | Intron | G:A | 0.0023 | 0.194 | 126 | 76 | 1 | 0.2802 | 0.188 | 30 | 14 | - |
| rs73520743 | 19:17883764 | Exon | A:C | 1.0 | 0.02 | - | 9 | 223 | 1.0 | 0.03 | - | 44 | 6 |
| rs112076606 | 19:17883785 | Intron | A:G | 0.448 | 0.214 | 2 | 55 | 81 | 1.0 | 0.214 | 1 | 16 | 17 |
| rs73520745 | 19:17883764 | Exon | C:T | 1.0 | 0.007 | 225 | 3 | - | 1.0 | 0 | 52 | - |
| rs775249401 | 19:17874645 | Intron | G:A | 1.0 | 0.064 | 217 | 22 | - | 1.0 | 0.038 | 46 | 5 | - |
| rs34850953 | 19:1782694 | Intron | G:T | 0.7398 | 0.077 | 202 | 33 | 2 | 1.0 | 0.028 | 43 | 9 | 1 |
| rs8103545 | 19:17875954 | Exon | C:T | 1.0 | 0.05 | 217 | 24 | - | 1.0 | 0.087 | 46 | 7 | - |

**TABLE 2** Molecular characteristics of SLC5A5 genetic variants among pregnant women ($n = 246$) and the subset of lactating women ($n = 55$).

chr: chromosome; bp, base pair; M, reference allele; m, alternative; HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; **Ensembl** release 96 — April 2019, retrieved 03 April 2020.
### TABLE 3 | Participant characteristics.

| Characteristics | All (n = 98) | Lactating women (n = 58) | Non-lactating women (n = 40) | *P*-value |
|-----------------|-------------|--------------------------|-----------------------------|---------|
| **Age (years)** | 27.2 ± 4.8  | 28.1 ± 4.7               | 27.9 ± 5.0                  | 0.750   |
| **Weight (kg)** | 69.4 (60.1–81.6) | 70.4 (69.4–81.5) | 68.6 (61.2–79.7) | 0.702   |
| **Height (m)**  | 159.1 ± 6.3 | 159.4 ± 6.3             | 158.4 ± 5.7                 | 0.634   |
| **MUAC (cm)**   | 29.8 (27.0–33.5) | 30.0 (27.0–33.6) | 29.0 (27.0–33.5) | 0.757   |
| **BMI (kg/m²)** | 27.5 (24.3–32.4) | 28.1 (24.1–32.4) | 26.2 (24.8–32.3) | 0.831   |
| **Country of birth (n = 95) [n(%)]** |  |  |  |  |
| South Africa   | 68 (69.4)  | 36 (64.3)               | 29 (82.9)                  | 0.044   |
| Zimbabwe       | 26 (26.5)  | 20 (35.7)               | 5 (14.3)                   |         |
| Lesotho        | 1 (1.0)    | –                       | 1 (2.9)                    |         |
| **Years in South Africa (n = 95) [n(%)]** |  |  |  |  |
| 1–2 years      | 3 (3.1)    | 3 (5.4)                 | –                          | 0.183   |
| >2–5 years     | 6 (6.1)    | 5 (8.9)                 | 1 (2.9)                    |         |
| >5 years       | 86 (87.8)  | 48 (85.7)               | 34 (97.1)                  |         |
| **Ethnicity (n = 97) [n(%)]** |  |  |  |  |
| Black          | 86 (88.6)  | 52 (89.7)               | 31 (88.6)                  | 0.676   |
| Colored        | 10 (10.2)  | 5 (8.6)                 | 4 (11.4)                   |         |
| Indian         | 1 (1.0)    | 1 (1.7)                 | –                          |         |
| **Education (n = 97) [n(%)]** |  |  |  |  |
| None/primary   | 4 (4.1)    | 2 (3.4)                 | 2 (5.7)                    | 0.324   |
| Grade 8–10     | 14 (14.3)  | 7 (12.1)                | 6 (17.1)                   |         |
| Grade 11–12    | 55 (56.1)  | 31 (53.4)               | 22 (62.9)                  |         |
| Tertiary       | 24 (24.5)  | 18 (31.0)               | 5 (14.3)                   |         |
| **Employment (n = 97) [n(%)]** |  |  |  |  |
| Unemployed     | 44 (44.9)  | 28 (48.3)               | 15 (42.9)                  | 0.640   |
| Self-employed  | 5 (5.1)    | 3 (5.2)                 | 2 (5.7)                    |         |
| Wage earner    | 46 (46.9)  | 25 (43.1)               | 18 (51.4)                  |         |
| Other          | 2 (2.0)    | 2 (3.4)                 | –                          |         |
| **Marital status (n = 97) [n(%)]** |  |  |  |  |
| With partner   | 64 (66.0)  | 40 (69.0)               | 21 (60.0)                  | 0.378   |
| Without partner| 33 (34.0)  | 18 (31.0)               | 14 (40.0)                  |         |
| **Grants (n = 92) [n(%)]** |  |  |  |  |
| None           | 65 (66.3)  | 44 (81.5)               | 19 (55.9)                  | 0.061   |
| Child support  | 24 (24.5)  | 10 (18.5)               | 12 (35.3)                  |         |
| Social relief  | 1 (1.0)    | –                       | 1 (1.0)                    |         |
| Disability     | 1 (1.0)    | –                       | 1 (1.0)                    |         |
| Old age        | 1 (1.0)    | –                       | 1(1.0)                     |         |
| **LSM score [n(%)]** |  |  |  |  |
| 1–4 (Low)      | 3 (3.0)    | 2 (3.4)                 | 1 (2.8)                    | 0.250   |
| 5–7 (Medium)   | 62 (63.3)  | 32 (55.2)               | 26 (72.2)                  |         |
| 8–10 (High)    | 33 (33.7)  | 24 (41.4)               | 9 (25.0)                   |         |
| **HIV status** |  |  |  |  |
| HIV-infected   | 28 (28.6)  | 16 (44.4)               | 11 (19.0)                  | 0.008   |
| **Median UIC (µg/L)** | 105 (66–154) | 95 (64–145.5) | 122 (73–207) | 0.259   |
| **Median BMIC (µg/L)** | –        | 104 (60–169) | –             | –       |
| **Estimated daily iodine excretion (µg/d)** |  |  |  |  |
| Urine          | 157.0 (99.3–231.0) | 142.4 (96.5–218.3) | 178.4 (168.8–309.5) | 0.259   |
| Breast milk    | –          | 80.9 (46.8–132.1)       | –                          | –       |
| Total daily estimated daily iodine excretion | – | 227.2 (167.4–346.7) | – | – |

MUAC, mid-upper arm circumference; BMI, body mass index; LSM, living standards measure; UIC, urinary iodine concentration; BMIC, breast milk iodine concentration. *Mean ± SD (all such values), †Median; 25th and 75th percentiles in parenthesis (all such values), ‡Individual estimated iodine daily excretion in urine was calculated by multiplying UIC by an assumed total daily urine volume of 1.5 L [12, 21, 22]. ‡Individual estimated iodine daily excretion in breast milk was calculated by multiplying individual BMIC by an assumed total daily breast milk volume of 0.78 L [12, 22]. *Estimated total daily iodine excretion is the sum of iodine excretion in urine and iodine excretion in breast milk [12]. †p-value for the Mann Whitney U test significance set at p ≤ 0.05.
TABLE 4 | Association of SLC5A5 variants with breast milk iodine concentrations and urinary iodine concentrations (n = 55).

| Genetic variant                  | (M): (m) | MM          | Mm + mm      | P-value* |
|----------------------------------|----------|-------------|--------------|----------|
| Breast milk iodine concentration (µg/L) |          |             |              |          |
| rs4808708                        | G:A      | 108.1 (67.3–175.5) | 107.9 (46.8–149.7) | 0.612    |
| rs7255301                        | G:A      | 112.9 (72.5–155.0) | 103.7 (44.1–150.1) | 0.802    |
| rs73520743                       | C:A      | 103.7 (57.7–166.9) | 109.2 (83.4–149.1) | 0.589    |
| rs112076606                      | A:G      | 142.1 (89.4–201.0) | 83.3 (39.4–143.4)  | 0.051    |
| rs73520745                       | G:A      | 109.2 (63.0–172.2) | 89.1 (68.0–148.4)  | 0.807    |
| rs775249401                      | G:A      | 86.8 (54.9–167.9) | 143.9 (122.4–169.3) | 0.042    |
| rs34850953                       | G:T      | 97.6 (60.5–147.1) | 142.1 (41.5–219.4) | 0.792    |
| rs8103545                        | C:T      | 108.4 (69.1–151.1) | 127.1 (89.1–191.1) | 0.561    |
| Urinary iodine concentration (µg/L) |          |             |              |          |
| rs4808708                         | G:A      | 111.4 (71.2–154.8) | 70.1 (45.6–82.8)  | 0.060    |
| rs7255301                         | G:A      | 106.0 (66.4–137.5) | 82.4 (60.8–165.1) | 0.967    |
| rs73520743                        | C:A      | 103.2 (66.2–137.6) | 91.1 (65.0–155.1) | 0.267    |
| rs112076606                       | A:G      | 133.0 (72.2–153.7) | 81.4 (58.4–119.1) | 0.081    |
| rs73520745                        | G:A      | 91.1 (62.2–133.9) | 137.7 (89.6–178.3) | 0.409    |
| rs775249401                       | G:A      | 102.0 (66.4–137.4) | 81.1 (48.6–145.2) | 0.912    |
| rs34850953                        | G:T      | 102.0 (67.2–137.6) | 66.1 (47.2–154.0) | 0.739    |
| rs8103545                        | C:T      | 91.1 (54.7–133.9) | 137.7 (66.4–183.1) | 0.345    |

M, reference allele in this study population; m, alternative allele in this study population; *p-value for the unadjusted general linear model, significance set at p < 0.05.

To our knowledge, this is the first study to assess the role of genetics in the transfer of iodine from plasma to breast milk in healthy lactating women of African descent using a targeted NGS approach. Genetic variants in the SLC5A5 gene in women of African descent living in urban South Africa were characterized and studied in the context of iodine transfer from plasma to breast milk during lactation. Our results suggest rs775249401(G/A) to be a candidate variant. Figure 2 shows the association between estimated total daily iodine excretion and fractional excretion in urine and breast milk in homozygotes GG (rs775249401(G/G)) and in the (A)-allele carriers of rs775249401(G/AA+A), stratified by UIC (UIC < 100 µg/L vs. UIC ≥ 100 µg/L). The fractional excretion of iodine in breast milk for rs775249401(G/G) with UIC < 100 µg/L was lower than in urine when estimated total daily iodine excretion was low, but higher with higher estimated total daily iodine excretion and exceeded the proportion of iodine excreted in urine (Figure 2A). In contrast, fractional excretion of iodine in breast milk of the (A)-allele carriers with UIC < 100 µg/L, was higher than in urine when the estimated total daily iodine excretion was low, but lower with a higher estimated total daily iodine excretion (Figure 2B). In both the rs775249401(G/G) and rs775249401(G/AA+A) genotype groups with UIC ≥ 100 µg/L, fractional excretion of iodine in breast milk was lower than fractional excretion of iodine into the urine (Figures 2C,D, respectively) and remained constant across estimated total daily iodine excretion. The association between rs775249401(G/A) and BMIC had a Cohen’s d of 0.88 and a partial eta squared η² = 0.078.
for mediating the transfer of iodine from plasma into breast milk, specifically among lactating women with poor iodine status. The function of the variant may not be observed when the iodine status is adequate, suggesting that adequate
iodine intake may counter the low iodine transfer associated with rs775249401 (GG).

We observed that in individuals harboring the rs775249401 (GG) genotype fractional excretion of iodine into the breast milk was lower than fractional excretion of iodine into urine with low iodine status, while in the rs775249401 (AG+AA) group fractional excretion of iodine into the breast milk was higher even when iodine status was low. Thus, lactating women carrying an (A) allele for rs775249401 (AG+AA) (19%; 10/53) had an adaptive advantage to maintain optimal levels of BMIC despite suboptimal iodine status. Our findings suggest a positive genetic drift from the ancestral rs775249401 (GG) to the alternative allele to rs775249401 (AG+AA), which leads to preferential excretion of iodine into the breast milk when iodine status is low. This preferential excretion of iodine in breast milk rather than in urine is likely a result of an increased expression of the NIS in the lactating breast and further supports the plausibility of a regulatory potential by the rs775249401.

The rs775249401 (G/A) variant is located in a promoter region between exon 4 and 5 (24), which is responsible for transcriptional control. It is speculated that the variant interferes with the affinity of transcription factors (TFs) to bind to their idyllic binding sites (25), thus altering affinity to transcription factors (25). The adaptation observed in our study suggests a physiological benefit for the infant, in that it ensures sufficient iodine in breast milk, especially during periods of low iodine intakes. Furthermore, the rs775249401 (G/A) variant is mainly present in African and not in Caucasian populations according to the Genome Aggregation Database (26). The variant rs775249401 (G/A) has a minor allele frequency (MAF) of 0.028 in this study population, which is higher than reported in the genome-wide association study for Africa populations (0.015) (24). A total of 14 missense and non-sense mutations in the SLC5A5 gene have been previously described in association with iodide transport defects in the thyroid (27). However, a better understanding of the impact that genetic variations in the SLC5A5 gene have on BMIC is as important.

Out of the 10 variants explored in our study, only rs775249401 was significantly associated with BMIC. One other variant, rs4808708 (G/A), was associated with UIC but not BMIC. The variant rs112076606 (A/G) showed a trend toward significance with both BMIC and UIC, whereby participants with the genotype rs112076606 (AA) had a higher BMIC and UIC compared to rs112076606 (AG+GG) carriers, suggesting AA homozygotes to have a higher overall iodine excretion compared to their G allele carrier counterparts.

To our knowledge, this is the first study to assess the role of genetics in the transfer of iodine from plasma to breast milk in healthy lactating women. Furthermore, our participants were healthy participants with no known history of thyroid disease. However, a major limitation of this study is the small sample size; based on an a posteriori sample size calculation, our study was only powered to determine associations of medium to large effect sizes. Thus, exploring the relationship of variants in the SLC5A5 gene locus in other studies with larger sample sizes is highly recommended.

**CONCLUSION**

Our results indicate that genetics may play an important role in the transfer of iodine into breast milk. The SLC5A5 gene variant rs775249401 (G/A) seems to be a candidate variant for further investigation. The A-allele carriers of rs775249401 (AG+AA) are likely to have higher iodine transfer into breast milk when in an iodine-deficient state compared to the homozygous GG group. Our results suggest that genetic variations in the SLC5A5 gene may play an important role in the transfer of iodine from plasma into breast milk and may partially explain variability in BMIC independent of maternal iodine intake. Therefore, these findings could contribute toward the body of evidence to improve precision nutrition strategies.

**DATA AVAILABILITY STATEMENT**

The data generated for the study are deposited in the sequence read archive (SRA), bioproject number (PRJNA735618), https://www.ncbi.nlm.nih.gov/bioproject/PRJNA735618.

**ETHICS STATEMENT**

This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving research study participants were approved by the Human Research Ethics Committee of the North-West University and the University of the Witwatersrand, Johannesburg. Permission to perform the NuPED study was given by the CEO of RMMCH, the RMMCH research review committee, the Gauteng Department of Health and the Johannesburg Health District’s District Research Committee. Written informed consent was obtained from all participants before enrolment. Consent for genetic testing were obtained.

**AUTHOR CONTRIBUTIONS**

LZ, JB, JN, and SS conceptualized and designed the study and wrote the first draft of the manuscript. SS, JB, LZ, EAS, LM, and CMS executed the study and collected data. LZ, MS, JB, and SS performed biochemical and statistical analyses. All authors critically evaluate the manuscript.

**FUNDING**

The NuPED study was supported in part by the National Research Foundation of South Africa, Unique Grant No. 99374 (EAS) (https://www.nrf.ac.za/) and the South African Medical Research Council under a Self-Initiated Research Grant (CMS) (http://www.mrc.ac.za/). The NuPED study has received further financial support from the University of South Africa’s Research Department for the grant Academic Qualification Improvement Programme (EAS) (www.unisa.ac.za). This sub-study was funded by the South Africa Sugar Association (Project 254) and ETH, Zurich.
ACKNOWLEDGMENTS

We would like to thank Dr. Amy Wise, Prof. A. Coovadia, Prof. H. Lombaard, Dr. E. Loock, Dr. R. Adams, Dr. R. Strehlau, Prof. M. Faber, Dr. O. Sotunde, Dr. M. Rothman, Dr. L. Siziba, and Mrs. C. Cooke, the sonographers and nurses of Rahima Moosa Mother and Child Hospital, the nurses at the primary healthcare clinics, the fieldworkers, and the study participants. We like to thank Prof. F. H. van der Westhuizen and Prof. A. A. van Dijk for the use of the IonTorrent sequencing facility, Biochemistry, North-West University.

REFERENCES

1. Smanik PA, Liu Q, Furminger TL, Ryy K, Xing S, Mzaazferri EL, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun. (1996) 226:339–45. doi: 10.1006/bbrc.1996.1358
2. Darrouzet E, Lindenthal S, Marcellin D, Pellequer J-L, Pourcher T. The sodium/iodide symporter: state of the art of its molecular characterization. Biochim Biophys Acta. (2014) 1838:244–53. doi: 10.1016/j.bbamem.2013.08.013
3. Tazebay UH, Wapnin IL, Levy O, Dohan O, Zachier LS, Zhao QH, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat. Med. (2000) 6:871–8. doi: 10.1038/78630
4. Mulrine HM, Skeaff SA, Ferguson EL, Gray AR, Valeix P. Breast-milk iodine concentration declines over the first 6 mo postpartum in iodine-deficient women. Am J Clin Nutr. (2010) 92:849–56. doi: 10.3945/ajcn.2010.29630
5. Bouhouch RR, Bouhouch S, Cherkau M, Aboussad A, Stinca S, Haldmann M, et al. Direct iodine supplementation of infants versus supplementation of their breastfeeding mothers: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. (2014) 2:197–209. doi: 10.1016/S2213-8587(13)70155-4
6. Dold S, Zimmermann MB, Baumgartner J, Davaz T, Galetti V, Braegger C, et al. A dose-response crossover iodine balance study to determine iodine requirements in early infancy. Am J Clin Nutr. (2016) 104:620–8. doi: 10.3945/ajcn.116.134049
7. Azizi F, Smyth P. Breastfeeding and maternal and infant iodine nutrition. Clin Endocrinol. (2009) 70:803–9. doi: 10.1111/j.1365-2265.2008.03442.x
8. Dror DK, Allen LH. Iodine in human milk: a systematic review. Adv Nutr. (2018) 9:3475–575. doi: 10.1093/advances/nmy020
9. Semba RD, Delange F. Iodine in human milk: perspectives for infant health. Nutr Rev. (2001) 59:269–78. doi: 10.1111/1753-4887.2001.tb05512.x
10. Dold S, Baumgartner J, Zeder C, Krzyzatek A, Osei J, Haldmann M, et al. Optimization of a new mass spectrometry method for measurement of breast milk iodine concentrations (BMIC) and an assessment of the effect of analytic method and timing of within-feed sample collection on BMIC. Thyroid. (2015) 26:287–95. doi: 10.1089/thy.2015.0317
11. Osei J, Andersson M, Van Der Reijden O, Dold S, Smuts C, Baumgartner J. Breast milk iodine concentrations, iodine status and thyroid function of breastfed infants aged 2-4 months and their mothers residing in a South African township. J Clin Res Pediatr Endocrinol. (2016) 8:381–91. doi: 10.4274/jcrpe.2729
12. Dold S, Zimmermann MB, Aboussad A, Cherkau M, Jia Q, Jukic T, et al. Breast milk iodine concentration is a more accurate biomarker of iodine status than urinary iodine concentration in exclusively breastfeeding women. 2. J Nutr. (2017) 147:528–37. doi: 10.3945/jn.116.242560
13. Nazeri P, Dallih M, Mehrabi Y, Hedayati M, Mirmiran P, Azizi F. Breast milk iodine concentration rather than maternal urinary iodine is a reliable indicator for monitoring iodine status of breastfed neonates. Biol Trace Elem Res. (2018) 185:71–7. doi: 10.1007/s12121-018-1246-9
14. Symington EA, Baumgartner J, Malan L, Zandberg L, Ricci C, Smuts CM. Nutrition during pregnancy and early development (NuPEd) in urban South Africa: a study protocol for a prospective cohort. BMC Pregnancy Childbirth. (2018) 18:308. doi: 10.1186/s12884-018-1943-6
15. Schoonen M, Seyffert A, Van Der Westhuizen FH, Smuts I. A bioinformatics pipeline for rare genetic diseases in South African patients. S Afr J Sci. (2019) 115:1–3. doi: 10.17159/sajs.2019/4876
16. Hardy GH. Mendelian proportions in a mixed population. Science. (1908) 28:49–50. doi: 10.1126/science.28.706.49
17. Pino S, Fang SL, Braverman LE. Ammonium persulfate: a safe alternative oxidizing reagent for measuring urinary iodine. Clin Chem. (1996) 42:239–43. doi: 10.1093/clinchem/42.2.239
18. Jooste PL, Strydom E. Methods for determination of iodine in urine and salt. Best Pract Res Clin Endocrinol Metab. (2010) 24:77–88. doi: 10.1016/j.beem.2009.08.006
19. WHO (World Health Organization). Urinary iodine concentrations for determining iodine status in populations. Geneva: World Health Organization (2013).
20. Jorgensen A, O’Leary P, James I, Skeaff S, Sherrif J. Assessment of breast milk iodine concentrations in lactating women in Western Australia. Nutrients. (2016) 8:699. doi: 10.3390/nu810699
21. Kirk AB, Kroll M, Dyke JV, Ohira S, Dias RA, Dasgupta PK. Perchlorate, iodine supplements, iodized salt and breast milk iodine content. Sci Total Environ. (2012) 420:73–8. doi: 10.1016/j.scitotenv.2012.01.045
22. IOM (Institute of Medicine). Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium and zinc. Washington DC: National Academy Press (2001).
23. Mizokami T, Fukushima S, Sishushima A, Kogai T, Hamada K, Maruta T, et al. Iodine transport defect and breast milk iodine. Eur Thyroid J. (2016) 5:145–8. doi: 10.1159/000446496
24. Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM, et al. Ensembl 2019. Nucleic Acids Res. (2019) 47:D745–51.
25. Suzuki Y, Tsunoda T, Sese J, Taira H, Mizushima-Sugano J, Hata H, et al. Identification and characterization of the potential promoter regions of 1031 kinds of human genes. Genome Res. (2001) 11:677–84. doi: 10.1101/gr.GR-1640R
26. Karczewski KJ, Francioli LC, Tao G, Cummings BB, Alfeldi J, Wang Q, et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. Nature. (2020) 581:434–43. doi: 10.1038/s41586-020-2308-7
27. Ravera S, Reyna-Neyra A, Ferrandino G, Amzel LM, Carrasco N. The sodium/iodide symporter (NIS): molecular physiology and preclinical and clinical applications. Annu. Rev. Physiol. (2017) 79:261–89. doi: 10.1146/annurev-physiol-022516-034125

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Siro, Baumgartner, Schoonen, Ngounda, Malan, Sympton, Smuts and Zandberg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.